Skip to main content
Fig. 6 | Molecular Cancer

Fig. 6

From: Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response

Fig. 6

Combination with CTLA-4 eradicates established HPV + tumors. When the tumor volume is about 50mm3, TC-1 tumor bearing mice are divided into groups treated with CCL11-E6E7 vaccination with or without anti-PD-1, anti PD-L1, anti-CTLA-4 administration every three days for a total of 6 times. A Tumor growth curve of plasmid vector control (Vehicle) and anti PD-1, anti PD-L1, anti-CTLA-4 administration alone, data were presented with mean ± SEM (n = 3 for vehicle, n = 5 for other groups). B-E kinetics of tumor growth was shown for individual mice of CCL11-E6E7 vaccination with or without anti PD-1, anti PD-L1, anti-CTLA-4 administration. (F) Flow cytometry analysis of E7 specific CD8 + T cell levels in each group on the 14th day after CCL11-E6E7 immunization data were presented with mean ± SEM (n = 3 for vehicle, n = 5 for other groups). G The different chemokines could shape antigen-induced immune types which are summarized in the diagram

Back to article page

Molecular Cancer

ISSN: 1476-4598